Meeting
2023 ASCO Annual Meeting
Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).
Authors
Shuchi Gulati
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Shuchi Gulati , Catherine Tangen , Christopher W. Ryan , Ulka N. Vaishampayan , Brian M. Shuch , Pedro C. Barata , Deepak K Pruthi , Cristiane Decat Bergerot , Abhishek Tripathi , Ian M Thompson Jr., Primo N Lara Jr., Sumanta Kumar Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01120249
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4546)
DOI
10.1200/JCO.2023.41.16_suppl.4546
Abstract #
4546
Poster Bd #
38
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events.
First Author: Martin Henner Voss
Poster
2023 ASCO Genitourinary Cancers Symposium
Real world outcomes of patients with non-clear cell renal cell carcinoma: A single Asian centre experience.
First Author: Johan W.K. Chan
Poster
2021 ASCO Annual Meeting
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
First Author: Chung-Han Lee
Poster
2020 ASCO Virtual Scientific Program
Validation of MAF biomarker for response prediction to adjuvant bisphosphonates in 2 clinical trials: AZURE and NSABP-B34.
First Author: Alexander H. G. Paterson